A potential molecular biomarker for palbociclib response is mutant KRAS status, first suggested through in vitro and in vivo work in tumor cell lines and mice where synthetic lethality was observed following CDK4 inhibition [25, 48]. Here, CDK4 is linked to neoplasm.